Article
  • Controlled Release of Nifedipine from Osmotic Pellet Based on Porous Membrane
  • Youn JY, Ku J, Kim BS, Kim MS, Lee B, Khang G, Lee HB
  • 니페디핀을 포함한 삼투성펠렛의 제조와 다공성막을 통한 약물방출제어
  • 윤주용, 구정, 김병수, 김문석, 이봉, 강길선, 이해방
Abstract
The osmotic delivery systems are based on osmosis. The transverse diffusion of water through a porous membrane from a medium with a low osmotic pressure to a medium with a high osmotic pressure. Nifedipine tablet dosage forms of Procardia XL®(Pfizer) and Adalat®(Bayer) are commercialized systems of this type that push-pull osmotic tablet operates successfully in delivering water-insoluble drugs. We prepared osmotic pellet system by fluidized bed coating method, and model-drug used nifedipine. The osmotic pellet system was composed of the core material, the swelling and osmotic pressure layer, the drug coating layer, and the porous membrane. This work is performed to investigate the effect of different factors, such as composition and thickness of membrane. The osmotic pellet has been successfully prepared by fluidized bed coating technology. The drug release behavior depended on the increase of CA ratio and thickness in porous membrane. The morphology of the osmotic pellet before and after the dissolution test were observed by SEM. In conclusion, we found that the drug release of osmotic pellet depended on the composition and coating thickness of porous membrane.

삼투압을 이용한 약물전달시스템은 소화관내의 물이 다공성막을 통하여 시스템 내부로 침투하면 시스템 내부에 있던 삼투압물질과 섞여 삼투압을 발생시키고, 이 삼투압의 힘으로 시스템 내부에 있는 약물을 시스템 외부로 일정한 속도로 방출하는 제제기술이다. 이러한 삼투압을 이용하여 상용화된 대표적인 제품으로 니페디핀을 모델약물로 한 타블렛 제형인 Procadia XL®(Pfizer)과 Adalat® (Bayer)가 널리 상용화되어 있다. 이번 연구에서는 타블렛 형태의 삼투압정을 유동층코팅 기술을 이용하여 삼투성펠렛으로 제조하였다. 삼투성펠렛은 수팽윤성 고분자와 삼투염을 포함한 시드층, 모델약물인 니페디핀을 포함하는 약물층 그리고 약물의 방출을 조절할 수 있는 다공성막으로 구성되어 있다. 본 연구에서는 다공성막으로 사용되는 초산셀룰로오스(CA)와 Eudragit® RS의 구성비와 코팅두께에 따른 약물방출 거동을 확인하였으며, 다공성막의 구성물질인 CA의 비가 증가할수록 또한 다공성막의 코팅두께가 증가할수록 같은 측정시간 때에 약물의 방출이 낮게 나타남을 확인하였다. 약물방출 전후의 펠렛의 형태를 확인하기 위하여 SEM을 측정하였다.

Keywords: nifedipine; osmotic pellet system; porous membrane; drug release; fluidized bed coater

References
  • 1. Khang G, Rhee JM, Lee HBMunundang Publishing Co., Seoul, Chap. 10, pp 135~154 (2004)
  •  
  • 2. Ray N, Theeuwes FEllis Horwood Ltd., Chichester (England), Chap. 7, pp 120~138 (1987)
  •  
  • 3. Kim MS, Lee SY, Khang G, Youn JY, Lee JS, Kil HJ, Jeong JC, Lee HBin Drug Delivery System Technology and Application, H. B. Lee and S. C. Song, Editors, Munundang Publishing Co., Seoul, Chap. 2, pp 10∼24 (2007)
  •  
  • 4. Lee HB, Lee DH, Kang BK, Jeung SY, Khang G, J. Korean Pharm. Sci., 32, 241 (2002)
  •  
  • 5. Azarmi S, Farid J, Nokhodchi A, Bahari-Saravi SM, Valizadeh H, Int. J. Pharm., 246, 171 (2002)
  •  
  • 6. Liu L, Khang G, Rhee JM, Lee HB, Korea Polym. J., 7(5), 289 (1999)
  •  
  • 7. Wong PSL, Barclay BL, Deters JC, Theeuwes FU.S. Patent 4,765,989 (1986)
  •  
  • 8. Jeong SC, Cho YH, Kim MS, Lee B, Khang G, Rhee JM, Lee HB, Polym.(Korea), 30(2), 112 (2006)
  •  
  • 9. Liu L, Khang G, Rhee JM, Lee HB, Bio-Med. Mater. Eng., 9, 297 (1999)
  •  
  • 10. Liu L, Ku J, Lee B, Rhee JM, Lee HB, J. Control. Release, 68, 145 (2000)
  •  
  • 11. Rao VM, Haslam JL, Stella VJ, J. Pharm. Sci., 90, 807 (2001)
  •  
  • 12. Thombre AG, Appel LE, Chidlaw MB, Daugherity PD, Dumont F, Evans LAF, Sutton SC, J. Control. Release, 94, 75 (2004)
  •  
  • 13. Jeong SC, Chon SK, Jo YH, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 29(3), 288 (2005)
  •  
  • 14. Liu L, Khang G, Rhee JM, Lee HB, Biomater. Res., 3, 47 (1999)
  •  
  • 15. Lee DH, Khang G, Lee HB, Biomater. Res., 5, 1 (2001)
  •  
  • 16. Makhija SN, Vavia PR, J. Control. Release, 89, 5 (2003)
  •  
  • 17. Liu L, Che B, Eur. J. Pharm. Sci., 64, 180 (2006)
  •  
  • 18. Ho H, Chen C, Sheu M, J. Control. Release, 68, 433 (2000)
  •  
  • 19. Wang Y, Winnik MA, Macromolecules, 23, 4731 (1990)
  •  
  • 20. Siepmann J, Lecomte F, Bodmeirer R, J. Control. Release, 60, 379 (1999)
  •  
  • 21. Saettone MF, Perini G, Rijli P, Rodriguez L, Cini M, Int. J. Pharm., 126, 83 (1995)
  •  
  • 22. Shah PS, Zatz JL, Drug. Dev. Ind. Pharm., 18, 1759 (1992)
  •  
  • 23. Okarter TU, Singla K, Drug. Dev. Ind. Pharm., 26, 323 (2000)
  •  
  • 24. Rowe RC, Kotaras AD, White EFT, Int. J. Pharm., 22, 57 (1984)
  •  
  • 25. Gutierrez-Rocca JC, McGinity JW, Int. J. Pharm., 103, 293 (1994)
  •  
  • 26. Niopas I, Daftsios AC, J. Pharm. Biomed. Anal., 32, 1213 (2003)
  •  
  • 27. Takahashi M, Mochizuki M, Itoh T, Ohta M, Chem Pharm Bull, 42, 333 (1994)
  •  
  • 28. Youn JY, Ku J, Lee SY, Kim BS, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 31(4), 329 (2007)
  •  
  • 29. Kage H, Abe R, Hattanda R, Zhou T, Ogura H, Matsuno Y, Powder Technol., 130(1-3), 203 (2003)
  •  
  • Polymer(Korea) 폴리머
  • Frequency : Bimonthly(odd)
    ISSN 0379-153X(Print)
    ISSN 2234-8077(Online)
    Abbr. Polym. Korea
  • 2023 Impact Factor : 0.4
  • Indexed in SCIE

This Article

  • 2008; 32(4): 328-333

    Published online Jul 25, 2008

  • Received on Dec 24, 2007
  • Accepted on Jan 15, 2008